Bassermann, F;Frescas, D;Guardavaccaro, D;Busino, L;Peschiaroli, A;Pagano, M
The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint.
Cell
2008
134
2
256-67

Schmidt, R;Bültmann, A;Fischel, S;Gillitzer, A;Cullen, P;Walch, A;Jost, P;Ungerer, M;Tolley, ND;Lindemann, S;Gawaz, M;Schömig, A;May, AE
Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes.
Circ Res
2008
102
3
302-9

Michallet, MC;Meylan, E;Ermolaeva, MA;Vazquez, J;Rebsamen, M;Curran, J;Poeck, H;Bscheider, M;Hartmann, G;Konig, M;Kalinke, U;Pasparakis, M;Tschopp, J
TRADD protein is an essential component of the RIG-like helicase antiviral pathway.
Immunity
2008
28
5
651-61

Lordick, F;Schulze, T
Molecular prognostic factors and new systemic therapies in gastric cancer
Onkologie
2008
14
4
389-+

Abbrederis, K;Herrmann, K;Meyer, ZBC;Fend, F;Geinitz, H;Rothling, N;Krause, B;Peschel, C;Lordick, F
Single agent cetuximab induces a decrease in the tumor glucose-uptake measured by 18F-fluorodeoxyglucose positron emission tomography in advanced squamous cell carcinoma of the esophagus
Ann Oncol
2008
19
53-53

Lorenzen, S;Porschen, R;Al-Batran, S;Hofheinz, R;Thuss-Patience, P;Möhler, M;Grabowski, P;Arnold, D;Greten, T;Müller, L;Gerecke, U;Rothling, N;Schuster, T;Peschel, C;Lordick, F
Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the arbeitsgemeinschaft internistische onkologie (AIO)
Ann Oncol
2008
19
13-13

Lordick, F;Ridwelski, K;Al-Batran, SE;Trarbach, T;Schlag, PM;Piso, P
[Treatment of gastric cancer]
Onkologie
2008
31 Suppl 5
32-9

Hartwig, W;Hartung, W;Strobel, O;Lordick, F;Büchler, MW;Werner, J
[Multimodal therapy of esophageal cancer]
Z Gastroenterol
2008
46
10
1207-13

Arnold, D;Höhler, T;Dittrich, C;Lordick, F;Seufferlein, T;Riemann, J;Wöll, E;Herrmann, T;Zubel, A;Schmoll, HJ
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
Ann Oncol
2008
19
8
1442-9

Heger, U;Weitz, J;Lordick, F
[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors]
Chirurg
2008
79
7
630-7